Antibodies against SARS-COV-2 and uses thereof
Patent Information
- Application Number
- JP2023525485
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-10-27
- Filing Date
- 2021-10-27
- Publication Date
- 2024-11-05
AI Technical Summary
【1675】 ヒットの選択は、中和アッセイのすべてのウェルで得られた効果%値の全体的分布を表す、Genedata Biologics(Genedata)を使用して作成したヒストグラムに基づいていた。選択基準(効果%、表E3-1にまとめられている)を、ヒットの頻度が減少するヒストグラムの尾部に視覚的に適用した。RBD:ACE2中和一次HTRFスクリーニングで陽性であったあらゆるクローンを、二次スクリーニング段階に持ち越した。
Abstract
Claims
1. A neutralizing antibody that specifically binds to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein and competes with the human ACE2 receptor for binding to the SARS-CoV-2 spike protein.
2. 2. The antibody of claim 1, comprising a variable heavy (VH) domain sequence comprising complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3, and a variable light (VL) domain sequence comprising complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein HCDR3 is HCDR3 of antibody IMPI-037 shown in Table 1a (SEQ ID NO: 182).
3. The antibody of claim 2, wherein the six CDRs are those of antibody IMPI-037 shown in Table 1a (SEQ ID NOs: 180-182, 185, 18, and 186).
4. The variable heavy (VH) and variable light (VL) domain sequences are, respectively: i. the variable heavy (VH) and variable light (VL) domain sequences of antibody IMPI-037 shown in Table 1a (SEQ ID NOs: 179 and 184), optionally with 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs) in the variable heavy (VH) domain sequence and optionally with 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs) in the variable light (VL) domain sequence; or ii. a sequence having at least 90% identity to the variable heavy (VH) and variable light (VL) domain sequences of antibody IMPI-037 shown in Table 1a, provided that the antibody has the six CDRs of antibody IMPI-037 shown in Table 1a; The antibody of claim 3 , comprising:
5. 5. The antibody of any one of claims 1 to 4, wherein the variable heavy (VH) domain and variable light (VL) domain sequences comprise the variable heavy (VH) and variable light (VL) domain sequences, respectively, of antibody IMPI-037 shown in Table 1a.
6. (i) any of claims 1 to 5 with respect to binding to the SARS-CoV-2 spike protein or (ii) binds to the same epitope on the SARS-CoV-2 spike protein as an antibody of any one of claims 1 to 5.
7. i. a human IgG1 antibody, optionally comprising the constant region sequence of SEQ ID NO:418; ii. a human IgG4 antibody, optionally comprising the constant region sequence of SEQ ID NO: 436; or iii. The antibody of any one of claims 1 to 6, comprising a kappa (κ) light chain constant region, preferably, the sequence of the kappa (κ) light chain constant region is SEQ ID NO:
448.
8. A nucleic acid comprising a sequence encoding the VH and / or VL domain of an antibody as defined in any one of claims 1 to 7.
9. A vector comprising the nucleic acid of claim 8; optionally, the vector is a CHO vector.
10. A host cell comprising the nucleic acid of claim 8 or the vector of claim 9.
11. The antibody according to any one of claims 1 to 7. An isolated nucleic acid encoding the antibody of any one of claims 1 to 7, or An isolated nucleic acid according to claim 8; A pharma- ceutically acceptable excipient; 23. A pharmaceutical composition comprising:
12. i. formulated for intravenous, intramuscular or subcutaneous administration; and / or ii. further comprising at least one additional therapeutic agent, optionally the additional therapeutic agent being at least one, preferably one or two, additional antibodies, optionally the at least one additional antibody being a. an antibody that specifically binds to the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike protein and competes with the human ACE2 receptor for binding to the SARS-CoV-2 spike protein; b. an antibody that specifically binds to the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike protein and does not compete with the human ACE2 receptor for binding to the SARS-CoV-2 spike protein; c. An antibody that specifically binds to the N-terminal domain (NTD) of the S1 subunit of the SARS-CoV-2 spike protein; d. an antibody that specifically binds to the S2 subunit of the SARS-CoV-2 spike protein; and e. Antibodies that preferentially bind to the trimeric form of the SARS-CoV-2 spike protein over the isolated RBD domain, S1 subunit, and S2 subunit of the SARS-CoV-2 spike protein. The pharmaceutical composition of claim 11 , wherein the pharmaceutical composition is selected from the group consisting of
13. A kit comprising the pharmaceutical composition of claim 11 or 12, optionally comprising: i. at least one additional therapeutic agent, optionally the additional therapeutic agent is an additional pharmaceutical composition comprising at least one, preferably one or two, additional antibodies, optionally the at least one additional antibody being a. Specific binding to the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike protein and binding to the SARS-CoV-2 spike protein; an antibody that competes with the human ACE2 receptor; b. an antibody that specifically binds to the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike protein and does not compete with the human ACE2 receptor for binding to the SARS-CoV-2 spike protein; c. An antibody that specifically binds to the N-terminal domain (NTD) of the S1 subunit of the SARS-CoV-2 spike protein; d. an antibody that specifically binds to the S2 subunit of the SARS-CoV-2 spike protein; and e. Antibodies that preferentially bind to the trimeric form of the SARS-CoV-2 spike protein over the isolated RBD domain, S1 subunit, and S2 subunit of the SARS-CoV-2 spike protein. and / or ii. a label or instructions for use in treating and / or preventing a SARS-CoV-2 associated disease or condition, such as COVID-19, in a human; optionally, the label or instructions include a marketing authorization number (e.g., an FDA or EMA approval number); optionally, the kit includes an IV or injection device that includes the antibody or fragment; The kit further comprises:
14. An antibody according to any one of claims 1 to 7 or a composition according to claim 11 or 12 for use as a medicament.
15. 13. The antibody of any one of claims 1 to 7, or the composition of claim 11 or 12, for use in a method for treating or preventing a SARS-CoV-2 associated disease or condition, said method comprising administering the antibody or composition to a patient.
16. i. the SARS-CoV-2 related disease or condition is COVID-19; and / or ii. The method further comprises administering at least one additional therapeutic agent, optionally: a. the administration of the additional therapeutic agent is simultaneous, separate or sequential; b. The additional therapeutic agent is at least one, preferably one or two, additional antibodies, optionally wherein the at least one additional antibody is (i) an antibody that specifically binds to the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike protein and competes with the human ACE2 receptor for binding to the SARS-CoV-2 spike protein; (ii) an antibody that specifically binds to the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike protein and does not compete with the human ACE2 receptor for binding to the SARS-CoV-2 spike protein; (iii) an antibody that specifically binds to the N-terminal domain (NTD) of the S1 subunit of the SARS-CoV-2 spike protein; (iv) an antibody that specifically binds to the S2 subunit of the SARS-CoV-2 spike protein; and (v) an antibody that preferentially binds to the trimeric form of the SARS-CoV-2 spike protein over the isolated RBD domain, S1 subunit, and S2 subunit of the SARS-CoV-2 spike protein; Selected from: An antibody for use according to claim 15, or a composition for use according to claim 15.
17. The method according to any one of claims 1 to 7 for determining the presence or absence of SARS-CoV-2 in a sample. Use of the antibody described in any one of claims 1 to 4.
18. 1. A method for determining the presence or absence of SARS-CoV-2 in a sample, comprising: Contacting the sample with an antibody according to any one of claims 1 to 7; and Examining the binding between the antibody and SARS-CoV-2 in the sample Including; The method wherein detection of binding indicates the presence of SARS-CoV-2 in the sample and the absence of binding indicates the absence of SARS-CoV-2 in the sample.
19. i. the antibody contains or is conjugated to a detectable label; ii. the sample is obtained from a human infected or suspected to be infected with SARS-CoV-2 and / or exhibiting one or more symptoms of a SARS-CoV-2 related disease or condition, such as COVID-19; and / or iii. The use according to claim 17 or the method according to claim 18, wherein the sample is a serum, plasma or whole blood sample, or an oral or nasal swab, urine, stool or cerebrospinal fluid (CFS), or the sample is from any organ or tissue suspected of being infected with SARS-CoV-2.
20. A diagnostic kit for the use according to claim 17 or 19 or the method according to claim 18 or 19 comprising an antibody according to any one of claims 1 to 7 and optionally one or more buffers, optionally i. the antibody contains or is conjugated to a detectable label; or ii. A diagnostic kit comprising a first reagent comprising the antibody of any one of claims 1 to 7, and a second reagent comprising a detector molecule that binds to the first reagent, optionally wherein the detector molecule comprises a detectable label or is an antibody conjugated to a detectable label.
